Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety Study of Chromium Picolinate + Biotin on Glucose and Cholesterol Control in T2DM

This study has been completed.
Sponsor:
Information provided by:
Nutrition 21, Inc.
ClinicalTrials.gov Identifier:
NCT00289354
First received: February 7, 2006
Last updated: NA
Last verified: February 2006
History: No changes posted
  Purpose

To evaluate the effect of the combination of chromium picolinate (600 μg Cr) + biotin (2 mg) versus placebo on glycosylated hemoglobin (HbA1c), lipid profiles (Total-C, HDL-C, LDL-C, TGs, TG/HDL ratio, etc), and pharmacoeconomic outcomes as measured at the Baseline Visit and 90 days later at the Final Visit. Secondarily, to measure the effect of chromium picolinate (600 μg Cr) + biotin (2 mg) versus placebo on patient quality of life, fasting and post-prandial blood sugar levels, fasting insulin, and anti-hyperglycemic medication usage.


Condition Intervention
Diabetes Mellitus, Type 2
Drug: Chromium Picolinate (600 mcg Cr) + biotin (2 mg)

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Randomized, Double Blinded, Placebo Controlled, Study to Evaluate Improvements in Glycemic Control, Lipid Levels, Quality of Life and Healthcare Costs After Daily Administration of Chromium Picolinate and Biotin in Patients With T2DM

Resource links provided by NLM:


Further study details as provided by Nutrition 21, Inc.:

Primary Outcome Measures:
  • HbA1c: Baseline and Final Visits
  • Lipid Panels (Total-C, HDL, LDL, LDL, VLDL, lipid ratios, etc)Baseline and Final Visits
  • Pharmacoeconomic outcomes (as deduced by changes in HbA1c)

Secondary Outcome Measures:
  • Fasting Plasma Glucose: Baseline and Final Visits
  • Fasting Insulin: Baseline and Final Visits
  • HOMA-IR and HOMA-BCF: Baseline and Final Visits
  • Quality of Life: Baseline and Final Visits
  • Post Prandial Glucose: Diary recordings of post meal values, 90 day continuous.
  • Change in Rx Antihyperglycemic agents: Assessed at baseline and compared to final visit.
  • HAMD-29: Change in depression/mood status; measured at baseline and final at a subset of two research centers. (n~30).
  • ANCOVAs: Treatment outcomes based on treatment group compared to gender, ethnicity, age, co-morbidities, Rx medications, glycemic states at entrance, lipid status at entrance.

Estimated Enrollment: 600
Study Start Date: March 2003
Estimated Study Completion Date: November 2005
Detailed Description:

There will be an Initial Pre-Screening Contact, two office visits (Baseline and Final), and two mid-study phone contacts with the subject during the course of the study. Volunteers will take either chromium picolinate (600 μg Cr) + biotin (2 mg) (n=400) or placebo (n=200) once daily just prior to the morning meal for 90 days. Assessments for glycosylated hemoglobin, lipid profiles, and quality of life will be taken at the Baseline Visit. After 90 days another set of assessments will be taken at the Final Visit for comparison with the baseline values. All subjects will under go a brief physical exam, a medical history assessment, and a comprehensive concomitant medications assessment as well as provide blood and urine samples at the baseline and final visits to ensure subject safety is maintained. The subject will be contacted, by a central call center, between visits at Day 30 and Day 60 to ensure study compliance by reminding the subject to take all doses of study product, perform the daily blood glucose monitoring, and complete the study diary daily.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosis of type 2 diabetes > 12 months.
  2. Male and female between the ages of 18 and 70 years, inclusive.
  3. HbA1c > 7.0%.
  4. Subject must be receiving an anti-hyperglycemic medication. Medication dosage must be stable for at least 60 days prior to entering trial. Insulin usage must be for rescue purposes only. Rescue insulin use may not be more than once per week.
  5. Subjects with a body mass index (BMI) >/= 25 and < 35.
  6. Subject must be ambulatory.
  7. Willing to perform self-administered blood glucose monitoring.
  8. Willing to complete all study related requirements.
  9. Subject will provide written consent to participate in the trial and this consent must be given voluntarily.

Exclusion Criteria:

  1. Diagnosis of type 1 diabetes.
  2. Hypoglycemic event requiring EMS intervention within 12 months.
  3. Diabetic Ketoacidosis (DKA) within 12 months.
  4. Subjects taking any supplement containing chromium picolinate within the last 90 days prior to enrollment.
  5. Subjects taking a supplement or multivitamin containing any other form of chromium > 120 mcg/daily within the last 30 days prior to enrollment.
  6. Creatinine > 2.0 x ULN; AST or ALT > 2.0 x ULN; Total Bilirubin > 1.5 x ULN
  7. COPD, CHF, Angina, HTN, MI, or any other CVD requiring hospitalization within 12 months.
  8. History of cerebrovascular accident (CVA), pulmonary embolism (PE), or an unresolved deep vein thrombosis (DVT).
  9. History of CABG, PTCA, or any other reperfusion therapy within 12 months.
  10. Seated systolic BP > 160 mmHg.
  11. Morbid obesity.
  12. Any psychiatric or mental health issue that would prevent the subject from completing the study. (e.g. Severe depression, schizophrenia, high suicide risk, bi-polar disorder, dementia, substance abuse, etc,)
  13. History of any serious immunosuppressive disorder or current immunosuppressive therapy.
  14. Female subjects who are pregnant or nursing, or are planning on becoming pregnant during the study.
  15. Any illness or complication factor that, in the opinion of the investigator, would jeopardize the subject’s health or well being by participating in the study or would interfere with the subject successfully completing the study.
  16. Current diagnosis of any uncontrolled metabolic disease that would affect carbohydrate or glucose metabolism other than type 2 diabetes. (e.g. hyper or hypothyroidism). (NOTE: Subject’s condition must be stable for > 12 months with no medication changes within the last 12 months preceding enrollment. Subject’s TSH must be within range of normality at the time of enrollment to qualify).
  17. Current participation in any other clinical research trial for any product or device, or participation in said clinical trials within 30 days prior to enrollment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00289354

Sponsors and Collaborators
Nutrition 21, Inc.
Investigators
Study Director: Manley R Finch Nutrition 21, Inc.
Principal Investigator: Cesar Albarracin, MD Alpha Therapy Center
  More Information

No publications provided by Nutrition 21, Inc.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00289354     History of Changes
Other Study ID Numbers: N 21 CPB-02003
Study First Received: February 7, 2006
Last Updated: February 7, 2006
Health Authority: United States: U.S. FDA (DSHEA)
United States: New England IRB

Keywords provided by Nutrition 21, Inc.:
chromium
chromium picolinate
type 2 diabetes mellitus
HbA1c
hyperglycemia
cholesterol

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Biotin
Chromium
Picolinic acid
Chelating Agents
Growth Substances
Iron Chelating Agents
Micronutrients
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Sequestering Agents
Trace Elements
Vitamin B Complex
Vitamins

ClinicalTrials.gov processed this record on November 20, 2014